

## NC Medicaid and NC Health Choice Pharmacy Prior Approval Request for Antinarcolepsy: Xywav

## **Beneficiary Information**

Beneficiary Last Name:		5. Beneficiary Gender:	
3. Beneficiary ID #:	4. Beneficiary Date	e of Birth:	5. Beneficiary Gender:
Prescriber Information			
C Drossribing Drovider NDI #			
7 Requester Contact Information	n - Name	Phone #:	Ext
7. Requester contact information	1 - Name.	1 none #.	LAU.
Drug Information			
8. Drug Name:	9. Stre	ngth:	10. Quantity Per 30 Days:
11. Length of Therapy (in days):	Initial Authorization: $\ \square$ up to 30 Days	☐ 60 Days ☐ 90 Days	☐ 120 Days ☐ 180 Days ☐ 365 Days
Reauthorization: □ up to 30 Days □ 60 Days □ 90 Days □ 120 Days □ 180 Days □ 365 Days			
Clinical Information			
1. Is the beneficiary 7 years of ag 2. Does the beneficiary have any 3. Does the beneficiary have succe 4. Has the beneficiary been evalu 5. Will the prescriber monitor the [GHB]) including, but not limite behavior, feigned cataplexy, et 6. Does the beneficiary have a di 7. Does the beneficiary have a di need to sleep or daytime lapse 8. Does the beneficiary have hyp medicine or substance use has For Diagnosis of Idiopathic Hype 9. Does the beneficiary have a di □ Yes □ No	r current use of alcohol or sedative hypnoticinic semialdehyde dehydrogenase deficieuated for history of drug abuse? ☐ Yes ☐ e beneficiary for signs of misuse or abuse ed to, the following: Use of increasingly latt.? ☐ Yes ☐ No agnosis of Cataplexy associated with Narcagnosis of Excessive Daytime Sleepiness of the signs of the secondary to another sleep secondary to another sleep secondary to another sleep secondary (questions 9 - 17) agnosis of idiopathic hypersomnia with days	tics?   Yes   No ency   Yes   No No of sodium oxybate (a.k.a. arge doses, increased freque colepsy?   Yes   No due to Narcolepsy with dai Yes   No p disorder, neurologic diso	gamma-hydroxybutyrate uency of use, drug seeking ily periods of irrepressible
11. Does Multiple Sleep Latency onset) or no SOREMPs, if the REN 12. Is the average sleep latency la	M latency on the preceding overnight slee ess than or equal to 8 minutes on MSLT? ne greater than or equal to 660 minutes?	ep study was less than or e	s, which are REM sleep periods within 15 minutes of sleep equal to 15 minutes?   Yes  No
<ul><li>14. Does the beneficiary have ca</li><li>15. Has hypersomnolence second</li><li>No</li><li>16. Is the beneficiary ≥ 18 years of</li></ul>	dary to another sleep disorder, neurologic	c disorder, medical conditi	ion, or by medicine or substance use been ruled out? $\Box$ <b>Yes</b> $\Box$
17. Has the beneficiary tried and with preferred formulation of moreor continuation of therapy, ple 18. For a diagnosis of Excessive E sleepiness from pre-treatment b Cleveland Adolescent Sleepiness	I failed on a preferred formulation of mod odafinil?  Yes  No ease answer questions above and below ropetime Sleepiness or Idiopathic Hypersor	relative to the beneficiary minia, has the beneficiary rig., Epworth Sleepiness Scal	responded to therapy with a reduction in excessive daytime slle, Stanford Sleepiness Scale, Karolinska Sleepiness Scale,

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Fax this form to: (833) 404-2393 Pharmacy PA Call Center: (833) 585-4309